HC Wainwright Issues Positive Forecast for DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price

DiaMedica Therapeutics (NASDAQ:DMAC) had its target price hoisted by HC Wainwright from $10.00 to $12.00 in a research note published on Friday,Benzinga reports. They currently have a buy rating on the stock.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $4.18 on Friday. DiaMedica Therapeutics has a 12-month low of $3.19 and a 12-month high of $6.82. The company has a market capitalization of $179.24 million, a PE ratio of -6.53 and a beta of 1.17. The firm’s 50-day moving average is $3.93 and its two-hundred day moving average is $4.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). During the same quarter last year, the business posted ($0.14) earnings per share. On average, analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Institutional investors have recently bought and sold shares of the business. Perigon Wealth Management LLC purchased a new position in shares of DiaMedica Therapeutics in the second quarter valued at $207,000. Goldman Sachs Group Inc. boosted its stake in shares of DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after purchasing an additional 52,854 shares during the period. Jane Street Group LLC boosted its stake in shares of DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after purchasing an additional 58,457 shares during the period. Royal Bank of Canada boosted its stake in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the period. Finally, World Investment Advisors boosted its stake in DiaMedica Therapeutics by 17.0% during the 1st quarter. World Investment Advisors now owns 25,650 shares of the company’s stock valued at $97,000 after acquiring an additional 3,735 shares during the last quarter. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.